Anteris makes DurAVR, a transcatheter heart valve that mimics a healthy human aortic valve, plus anti-calcification tissue for surgical repairs—think a precision-engineered replacement part for a failing heart valve.
No meaningful revenue yet; the company burns cash, with net losses of USD 0.09B in 2025 and USD 0.08B in 2024. Gross margins swing wildly (46.84% in 2024, -16.57% in 2025), but the business is pre-commercial and unprofitable.
DurAVR's biomimetic design and ADAPT tissue are patented, but Edwards Lifesciences and Medtronic dominate TAVR with established sales networks and clinical data. Anteris has no approved product or revenue, so its moat is unproven and easily bypassed by larger,
Key events, in time order
None yet
None yet
Anteris Technologies (AVR) is positioned for acquisition due to a significant stake taken by Medtronic, aligning with strong growth projections in the TAVR market.
Main discussion
$AVR Long common shares The global TAVR (Transcatheter Aortic Valve Replacement) is projected to reach USD 16.5 billion by 2035, expanding at a compound annual growth rate (CAGR) of 9.8% during the forecast period from 2026 to 2035
$AVR 19.9% stake by $MDT earlier this year bodes well for $AVR acquisition in near future. Nice nuggets by @jayabacus on this name Slowly building a position in $AVR ⬇️⬇️
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
